The Valley Desk

Clinical trial reportNature agingPublished

The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson's disease

11 of 43 authors shown in byline order.

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Cooper Medical School of Rowan University, Rowan University. Affiliation source

Publication record

Type
Clinical trial report
Venue
Nature aging
Published
Subject terms
Humans; Parkinson Disease; Pyrimidines; Proto-Oncogene Proteins c-abl; Protein Kinase Inhibitors; Treatment Outcome; Double-Blind Method; Aged; Middle Aged; Female; Male; Tyrosine Kinase Inhibitors
PubMed ID
41721133
PubMed Central ID
PMC13004677
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal